Latest news with #PatanjaliAyurved
Time of India
22-07-2025
- Health
- Time of India
Can Ayurveda replace OTC pills?
Image Credit : Canva In today's fast-paced world, over-the-counter (OTC) pills have become a common recourse for managing everything from headaches and colds to digestive discomfort and minor aches. Their convenience and quick relief are undeniable. However, alongside this growing reliance on quick fixes, there has been a renewed interest in Ayurveda , the ancient system of medicine that originated in India more than 5,000 years ago. With companies like Patanjali introducing Ayurvedic medicines into the mainstream, the question is: Can Ayurveda replace OTC pills? To respond to this thoughtfully, one needs to consider the principles of Ayurveda, its method versus traditional OTC pills, and the teachings offered by adherents like Baba Ramdev, without succumbing to the pitfall of mere marketing campaign sound bites. Ayurveda: Treating the root, not just symptoms Image Credit : Canva Health, as per Ayurveda, is the equilibrium of body, mind, and spirit sustained by optimal diet, lifestyle, and natural treatments. In contrast to OTC pills that tend to act on the symptoms directly, like alleviating pain, dropping fever, or decongesting; Ayurveda is focused on curing the causative factor of imbalance or disease. The ancient texts refer to this as "Nidana Parivarjana" or elimination of causative factors along with "Shodhana" (cleansing) and "Panchakarma" (detoxification therapies). Patanjali Ayurved, one of the leading institutions promoting Ayurvedic products in the present era, demonstrates such principles through its herbal formulations and wellness practices. Still, it needs to be made clear that Ayurveda is not placed alternatively as a substitute for OTC medicines but as a complementary or alternative route to holistic well-being. The Real-World Implications: When can Ayurveda sub for OTC Pills? Although Ayurveda's integrated approach is to be appreciated, practical implementation needs sophistication: Acute cases : OTC medications are best in acute or emergencies like fever, infections requiring antibiotics, or an acute allergic reaction. In such cases, quick-acting allopathic medicines are the key to avoiding complications. Ayurveda typically does not intend to substitute instant pharmacological treatment in these situations. Chronic and lifestyle disorders : Diseases related to lifestyle, like arthritis, digestive issues, stress-related disorders, or chronic fatigue, can often benefit from Ayurvedic therapies. Since these conditions develop over time through imbalance and poor habits, Ayurveda's emphasis on correcting root causes fits well. Many patients seek Ayurvedic rejuvenation therapies alongside or after conventional treatment. Side effects and dependence : Chronic or indiscriminate consumption of OTC pills at times may produce side effects or dependence. Ayurveda's holistic methodology adopts herbs and dietetic changes that can be less harmful in their adverse effects, though quality control and standardisation are issues. Integrative approach: Convergence of Ayurveda and contemporary medicine The majority of healthcare professionals recommend an integrative practice whereby Ayurveda and allopathy (conventional medicine) blend perfectly. OTC tablets provide swift relief, yet Ayurveda facilitates healing and sustained wellness. This synergy needs to be carried out under careful medical observation and patient sensitivity. Real-World example: Testimony shared by Rama Pathak, Homemaker The effect of Ayurvedic treatment is best realised through everyday stories such as that of Rama, who described her deep healing via Ayurvedic treatment: She said, "I began to see the changes day by day. It started small, wriggling of toes, and then one leg could move. Gradually, sensation passed through my lower limbs. I gained sitting balance, regained the power to stand and then walk with support, and lastly, in three and a half months of treatment, I could walk independently." This affidavit underscores Ayurveda's ability to promote healing and restore function where modern drugs might be limited, particularly in chronic or rehabilitative situations. Ayurveda provides a distinct philosophy and practice of long-term health by dealing with the imbalances underlying the body and restoring natural balance. Though it cannot be seen as a blanket substitute for OTC pills, especially in emergencies or where immediate intervention is needed, it most definitely presents a valuable avenue for dealing with chronic conditions and inducing wellness. Real-World example: Testimony shared by Priya Srivastava, Journalist Priya Srivastava's experience echoes the holistic benefits of Ayurveda. After struggling with chronic fatigue and digestive issues that did not respond satisfactorily to OTC pills, she adopted Ayurvedic therapies on the advice of a certified practitioner. Priya said, 'Within a month of following the prescribed herbal remedies, dietary adjustments, and lifestyle recommendations, my energy levels improved, my digestion normalized, and I felt a renewed sense of general well-being. I experienced fewer relapses and far less dependence on quick-fix solutions.' As the words of Baba Ramdev indicate, Ayurveda's advantage is in its root-source methodology as opposed to symptom suppression in and of itself. For one who is willing to accept lifestyle modification, food regimen discipline, and herbal remedies, Ayurveda can be an extremely effective addition, or in certain instances, a substitute for, the fast-fix ideology prevalent in today's OTC pill culture. Finally, whether or not to depend on Ayurveda, OTC, or both should be individualised, hopefully under educated and professional advice, to guarantee safety, effectiveness, and integral care.
&w=3840&q=100)
Business Standard
18-07-2025
- Business
- Business Standard
Patanjali Foods shares rally 17% in 1 week, eyes record high; here's why
Patanjali Foods share price today Patanjali Foods shares gained 2 per cent to ₹1,944.90 on the BSE in Friday's intraday trade, in an otherwise weak market, extending its rally into fifth straight trading day. The stock of the consumer goods company has surged 17 per cent during the period. Further, it is trading close to its all-time high level of ₹2,030, touched on September 4, 2024. At 10:03 AM, Patanjali Foods share price was trading 1.7 per cent higher at ₹1,942.10, as compared to 0.37 per cent decline in the BSE Sensex. CATCH STOCK MARKET UPDATES TODAY LIVE What's driving Patanjali Foods stock price? The board of directors of Patanjali Foods, in its meeting held on Thursday, July 17, 2025, recommended to issue bonus shares in the ratio of 2:1 i.e. two new equity shares each for every one existing equity share held by eligible equity shareholders of the company as on record date. The bonus issue is subject to approval of the shareholders of the company, by capitalisation of capital redemption reserve and / or securities premium and / or general reserve, the company said in exchange filing. Business overview Patanjali Foods enjoys a healthy market position across several product categories. It is the second-largest player in India's branded edible oil market, the market leader in the palm oil segment and second in position in the soybean oil segment. It is also the market leader in the soya protein segment, commanding a 35-40 per cent market share. Further, the company is the fourth-largest player in India in the biscuits segment and in the oral care market. It is also among the largest players in India in the product segments of cow ghee and honey. While the erstwhile Ruchi Soya Industries was largely focused on the edible oil business, Patanjali Foods has gradually diversified the business through the acquisition of various FMCG segments from Patanjali Ayurved. In addition to being margin accretive, these segments have also aided the diversification of Patanjali Foods' portfolio and mitigated the impact of the inherent risks associated with the edible oil segment to a certain extent. ALSO READ | Multiple order wins lift Afcons Infrastructure shares by 6%; details here The contribution of the FMCG segment to Patanjali Foods overall revenues has increased to around 30 per cent in FY2025 and is expected to grow further over the near to medium term, leading to further diversification of the business and stabilisation of earnings, according to Icra. In the absence of any major debt-funded capex, the debt protection metrics are expected to remain strong in the long term as well. Its healthy financial profile is also aided by a strong liquidity position owing to healthy cash balances, liquid investments and unutilised working capital limits, the rating agency said in rationale. As around 50 per cent of the revenue from the edible oils business is generated from palm oil, Patanjali Foods is also working towards expanding its palm plantation business, to reduce its import dependence for crude palm oil. In addition, the company has diversified to the FMCG segment to provide further stability to its earnings. About Patanjali Foods Patanjali Foods (formerly known as Ruchi Soya Industries Limited) is engaged primarily in the business of processing of oil-seeds, refining of crude oil for edible use, production of oil meal, food products from soya and value added products from downstream and upstream processing. The Company is also engaged in the Fast-Moving Consumer Goods (FMCG) and Fast Moving Health Goods (FMHG) business consisting mainly of food, biscuits and nutraceutical products.
&w=3840&q=100)
Business Standard
15-07-2025
- Business
- Business Standard
Patanjali Foods up 2% as board to consider bonus shares on July 17
Patanjali Foods shares rose 2.3 per cent on Tuesday, registering an intraday high at ₹1,713.95 per share. At 11:53 AM, Patanjali Foods share price was trading higher by 1.88 per cent at ₹1,706.85 per share on the BSE. In comparison, the BSE Sensex was up 0.45 per cent at 82,624.98. The company's market capitalisation stood at ₹61,874.39 crore. The 52-week high of the stock was at ₹2,030 per share and the 52-week low of the stock was at ₹1,541 per share. Patanjali bonus issue details On Monday, after market hours, the company announced that in a meeting on Thursday, July 17, 2025, the board will mull bonus shares. "We may inform you that a meeting of the board of directors of the company is scheduled to be held on Thursday, July 17, 2025, inter alia to consider a proposal for issue of bonus shares subject to approval of the shareholders of the company," the filing read. A bonus issue (also called a bonus share issue or capitalisation issue) is when a company issues free additional shares to its existing shareholders, based on the number of shares they already hold. Meanwhile, recently, the Delhi High Court passed an interim order directing Patanjali Ayurved to take down advertisements that allegedly disparage Dabur's chyawanprash products. This came in response to a suit filed by Dabur India Ltd in December 2024, accusing Patanjali Ayurved of making misleading claims about its flagship Ayurvedic product. Justice Mini Pushkarna issued the order after finding that the contested advertisements were problematic under the law governing commercial speech and product representation. The case stems from an advertisement featuring Patanjali Ayurved's co-founder Ramdev, who is shown casting doubt on the authenticity of competing Chyawanprash brands. According to the lawsuit, the ad shows that only Patanjali's Chyawanprash is "original", while others are shown as lacking the requisite Ayurvedic and Vedic knowledge to manufacture authentic formulations. About Patanjali Foods Patanjali Foods is a FMCG company that offers a wide range of household essentials. From nourishing foods to home and personal care solutions.
&w=3840&q=100)
Business Standard
15-07-2025
- Business
- Business Standard
Patanjali Foods climbs 2% as board to consider bonus shares on July 17
Patanjali Foods shares rose 2.3 per cent on Tuesday, registering an intraday high at ₹1,713.95 per share. At 11:53 AM, Patanjali Foods share price was trading higher by 1.88 per cent at ₹1,706.85 per share on the BSE. In comparison, the BSE Sensex was up 0.45 per cent at 82,624.98. The company's market capitalisation stood at ₹61,874.39 crore. The 52-week high of the stock was at ₹2,030 per share and the 52-week low of the stock was at ₹1,541 per share. Patanjali bonus issue details On Monday, after market hours, the company announced that in a meeting on Thursday, July 17, 2025, the board will mull bonus shares. "We may inform you that a meeting of the board of directors of the company is scheduled to be held on Thursday, July 17, 2025, inter alia to consider a proposal for issue of bonus shares subject to approval of the shareholders of the company," the filing read. A bonus issue (also called a bonus share issue or capitalisation issue) is when a company issues free additional shares to its existing shareholders, based on the number of shares they already hold. Meanwhile, recently, the Delhi High Court passed an interim order directing Patanjali Ayurved to take down advertisements that allegedly disparage Dabur's chyawanprash products. This came in response to a suit filed by Dabur India Ltd in December 2024, accusing Patanjali Ayurved of making misleading claims about its flagship Ayurvedic product. Justice Mini Pushkarna issued the order after finding that the contested advertisements were problematic under the law governing commercial speech and product representation. The case stems from an advertisement featuring Patanjali Ayurved's co-founder Ramdev, who is shown casting doubt on the authenticity of competing Chyawanprash brands. According to the lawsuit, the ad shows that only Patanjali's Chyawanprash is "original", while others are shown as lacking the requisite Ayurvedic and Vedic knowledge to manufacture authentic formulations. About Patanjali Foods Patanjali Foods is a FMCG company that offers a wide range of household essentials. From nourishing foods to home and personal care solutions.
Business Upturn
03-07-2025
- Business
- Business Upturn
Corporate highlights for today, July 3: Bajaj Finance, Reliance Retail, SpiceJet, Patanjali, HDFC Bank, Tata Power, GMR Airports, Vedanta, Nykaa, MOIL, Bosch and more
By Aditya Bhagchandani Published on July 3, 2025, 22:30 IST Indian corporates witnessed a busy day with several notable developments: CG Power and Industrial Solutions successfully closed its QIP at ₹660 per share, raising funds from institutional investors at ~2.8% discount. Bajaj Finance posted a robust Q1FY26 business update: customer franchise rose to 106.51 million (+21% YoY), new loans booked at 13.49 million (+23% YoY), AUM jumped 25% YoY to ₹4.41 lakh crore. Reliance Retail announced a strategic minority stake in UK-based FaceGym to bring its facial workout studios to India through Tira and standalone outlets. SpiceJet clarified that a cosmetic interior window frame became loose mid-flight on its Goa-Pune service, with no safety impact. Dabur India won an interim injunction from the Delhi High Court restraining Patanjali Ayurved from airing allegedly disparaging ads against Dabur chyawanprash. HDFC Bank CEO Sashidhar Jagdishan moved the Supreme Court seeking to quash an FIR filed by Lilavati Trust after three Bombay HC judges recused from hearing his plea. Tata Power was ordered to pay $490.32 million in damages to Kleros Capital Partners over a breach of NDA, even as it reported strong Q4 earnings. GMR Airports saw shares rise after TDSAT asked AERA to recalculate the HRAB for DIAL airport, which could raise tariffs and profitability. Reliance Communications was classified as 'fraud' by SBI, implicating former director Anil Ambani over alleged fund diversion of ~₹12,692 crore. Vedanta reported Q1FY26 production: aluminium output at 575,000 tonnes (+2% QoQ) and zinc output at 252,000 tonnes (-4% QoQ). Nykaa (FSN E-Commerce) shares fell after a ~2.3% block deal by the Banga family as they pared stake. MOIL reported a 15% YoY increase in manganese ore production in Q1FY26 and a 24% YoY rise in sales. Bosch announced plans to invest ₹800 crore over the next two years for localisation of EV components and new mobility solutions. Quess Corp said it plans to divest non-core businesses and focus on scaling staffing and digital services verticals. These developments reflect the legal, operational, financial, and strategic actions shaping corporate India today. Disclaimer: The information provided here is for informational purposes only and should not be considered as financial or investment advice. Please conduct your own research or consult a professional advisor before making any investment decisions. Neither the author nor the publisher is liable for any actions taken based on this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
